Icosavax, Inc.
ICVX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $763 | $665 | $643 | $1,602 |
| Gross Profit | -$763 | -$665 | -$643 | -$1,602 |
| % Margin | – | – | – | – |
| R&D Expenses | $16,668 | $19,826 | $17,357 | $16,193 |
| G&A Expenses | $8,607 | $9,129 | $9,165 | $8,938 |
| SG&A Expenses | $8,607 | $9,129 | $9,165 | $8,938 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $582 |
| Operating Expenses | $25,275 | $28,955 | $26,522 | $25,131 |
| Operating Income | -$25,275 | -$28,955 | -$26,522 | -$25,131 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,234 | $2,458 | $1,961 | $1,518 |
| Pre-Tax Income | -$22,041 | -$26,497 | -$24,561 | -$23,613 |
| Tax Expense | $0 | $0 | -$1,961 | -$2,133 |
| Net Income | -$22,041 | -$26,497 | -$22,600 | -$21,480 |
| % Margin | – | – | – | – |
| EPS | -0.44 | -0.59 | -0.55 | -0.54 |
| % Growth | 25.4% | -7.3% | -1.9% | – |
| EPS Diluted | -0.44 | -0.59 | -0.55 | -0.54 |
| Weighted Avg Shares Out | 50,031 | 44,771 | 41,265 | 39,811 |
| Weighted Avg Shares Out Dil | 50,031 | 44,771 | 41,265 | 39,811 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,234 | $2,458 | $1,961 | $1,518 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $763 | $665 | $643 | $619 |
| EBITDA | -$25,275 | -$28,955 | -$24,561 | -$25,131 |
| % Margin | – | – | – | – |